UK-based Scancell Holdings has selected a lead COVID-19 vaccine candidate – SN14 – to advance through further development and into clinical trials. Scancell’s DNA vaccines target dendritic cells to stimulate high avidity T cells that identify and destroy diseased cells. The company evaluated 15 vaccine candidates, containing different S and N components combined with a number of targeting technologies, for the ‘best’ T cell and antibody responses. Source: Pharmatimes 18/12/2020